Trade-Ideas LLC identified

Affymetrix

(

AFFX

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Affymetrix as such a stock due to the following factors:

  • AFFX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $69.1 million.
  • AFFX traded 1.5 million shares today in the pre-market hours as of 8:23 AM, representing 29.9% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AFFX with the Ticky from Trade-Ideas. See the FREE profile for AFFX NOW at Trade-Ideas

More details on AFFX:

Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level. The company operates in two segments, Affymetrix Core and eBioscience. AFFX has a PE ratio of 108. Currently there are no analysts that rate Affymetrix a buy, 1 analyst rates it a sell, and 5 rate it a hold.

The average volume for Affymetrix has been 3.0 million shares per day over the past 30 days. Affymetrix has a market cap of $1.2 billion and is part of the technology sector and electronics industry. The stock has a beta of -0.70 and a short float of 17.8% with 1.83 days to cover. Shares are up 48% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Affymetrix as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow.

Highlights from the ratings report include:

  • Despite its growing revenue, the company underperformed as compared with the industry average of 4.2%. Since the same quarter one year prior, revenues slightly increased by 2.2%. This growth in revenue does not appear to have trickled down to the company's bottom line, displaying stagnant earnings per share.
  • The current debt-to-equity ratio, 0.37, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 2.88, which clearly demonstrates the ability to cover short-term cash needs.
  • The gross profit margin for AFFYMETRIX INC is currently very high, coming in at 70.55%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 4.24% trails the industry average.
  • The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry average. The net income has decreased by 21.5% when compared to the same quarter one year ago, dropping from $5.17 million to $4.06 million.
  • Net operating cash flow has significantly decreased to $2.28 million or 84.98% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.